Prograf The active ingredient of the drug (Tacrolimus) binds to cytosolic protein (FKBP12), responsible for the intracellular accumulation of the drug. Designed for the prevention and treatment of allograft liver, kidneys and heart rejection reactions, including those resistant to standard immunosuppressive therapy regimes.
Your order will be packed safe and secure and dispatched within 24 hours. This is exactly how your parcel will look like (pictures of a real shipping item). It has a size and a look of a regular private letter (9.4x4.3x0.3 inches or 24x11x0.7cm) and it does not disclose its contents
Prograf Product Description
Prograf is an immunosuppressant, which inhibits formation of cytotoxic lymphocytes, responsible for graft rejection. Immunosuppressant Prograf controls the body's immune response to transplantation of a new organ and reduces the risk of the transplant rejection.
Prograf is prescribed to adults and elderly patients to prevent graft rejection of allogeneic liver, kidney and/or heart. This immunosuppressant can be administered to both adults and pediatric patients.
Children aged from 4 months to 18 years can be prescribed with Prograf only to prevent liver transplant rejection. Prograf efficacy in preventing rejection of kidney and heart transplant in pediatric patients has not been proven.
The dose of immunosuppressant Prograf should be matched based on the clinical assessment of the risk of rejection, the patient’s individual tolerance and body weight. The recommended dose of immunosuppressant Prograf for adults may vary from 0.075 mg to 0.2 mg per kg of body weight per day. Prograf daily dose for infants and children with a liver transplant may vary from 0.15 mg to 0.20 mg per kg of body weight.
If over 6 hours have passed after the missed intake of Prograf, then skip the missed dose. Do not double a dose and do not take extra immunosuppressants to make up for the missed dose of Prograf.
Like other immunosuppressants, Prograf is characterized by high nephrotoxic potential. Therefore, regular monitoring of renal function is recommended during the immunosuppressant therapy.
Immunosuppressant Prograf should be stored in its original package at controlled room temperature below 30°C.
Prograf Safety Information
The patients taking Prograf are considered to be at risk because of long-term use of the immunosuppressant. In long-term application of Prograf, the risk for malignancies, particularly, skin lymphoma is increased. To reduce the risk for developing lymphoma, the patients are recommended to avoid long-term exposure to sunlight and being outdoors in direct sunlight too long uncovered by clothing.
Information about prevention of organ rejection, described in this review of Prograf, is provided solely as general information. This information cannot be relied as a substitute for medical advice of the transplant doctor, surgeon or other health specialist. The online pharmacy assumes no responsibility for any loss suffered by the use or misuse of information on organ rejection and Prograf.
Prograf Side Effects
Prograf may cause in the patients having kidney transplant: infection, tremor, high blood pressure, abnormal renal function, constipation, vomiting, diarrhea, headache, abdominal pain, insomnia, nausea, urinary tract infection, leucopenia, asthenia, pain or anaemia.The patients, who underwent liver or heart transplantation, may experience during the immunosuppressant therapy: paraesthesia, leukocytosis, high blood sugar, high potassium, diabetes, itch or abnormalities of magnesium levels.